The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2022 | Advantages & uses of mass spectrometry in the diagnosis and monitoring of multiple myeloma
Noemi Puig, MD, PhD, University Hospital Salamanca, Salamanca, Spain, highlights the advantages of mass spectrometry over immunofixation in the diagnosis and monitoring of multiple myeloma. Dr Puig explains that mass spectrometry is more sensitive and allows identifying patients who will have worse outcomes better than immunofixation. In addition, mass spectrometry can discriminate between the patient’s M-protein and therapeutic monoclonal antibodies, thereby leading to better treatment response monitoring. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
